Sonidegib
Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].
Product Specifications
CAS Number
[956697-53-3]
Product Name Alternative
Erismodegib; LDE225; NVP-LDE225
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Smo
Type
Reference compound
Related Pathways
Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lde225.html
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
Molecular Formula
C26H26F3N3O3
Molecular Weight
485.50
Precautions
H302, H315, H319, H335
References & Citations
[1]Pan S, et al. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2010 Mar 16;1 (3) :130-4.|[2]Irvine DA, et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep. 2016 May 9;6:25476.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
BioRxiv. 2023 Nov 6:2023.11.03.565570.|bioRxiv. 2024 Jul 25.|bioRxiv. 2024 Nov 4:2024.10.08.617155.|bioRxiv. 2025 Oct 11.|Cell Physiol Biochem. 2018;47 (4) :1352-1364.|J Pathol. 2025 Nov 6.|SSRN. 2025 Jul 25.|Tissue Cell. 2024 Nov 28:92:102643.|J Genet Genomics. 2018 May 20;45 (5) :237-246.|Nat Med. 2018 Nov;24 (11) :1752-1761. |Patent. US20180263995A1.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
